Abstract
Edwards Lifesciences will report fiscal third‑quarter 2026 results on November 4, 2026 Post-Mkt; consensus points to mid-teens earnings growth, with investors focused on transcatheter momentum, U.S. coverage updates, and the first full quarter benefiting from recent product clearances.
Market Forecast
For the fiscal third quarter, projections indicate revenue of 1.68 billion US dollars, up 12.07% year over year, with adjusted EPS of 0.74, up 24.19% year over year; forecast EBIT stands at 478.99 million US dollars, up 22.93% year over year. Margin forecasts were not provided, though the company exited the prior quarter with a strong gross profit margin baseline.
The main business remains transcatheter heart valve therapy, which delivered 1.46 billion US dollars last quarter and continues to be underpinned by steady U.S. procedure volumes and broader international adoption; management has indicated that 2026 TAVR growth should be in the 8%–9% range for the year. Within product-line priorities, transcatheter aortic valve therapies are the most promising near-term growth segment, with management’s 2026 outlook implying mid-to-high single-digit expansion and sustained operating leverage as the platform scales.
Last Quarter Review
In the fiscal second quarter, Edwards Lifesciences reported revenue of 1.74 billion US dollars (up 13.63% year over year), a gross profit margin of 77.46%, GAAP net profit attributable to shareholders of 242.00 million US dollars, a net profit margin of 13.89%, and adjusted EPS of 0.78 (up 16.42% year over year).
One notable highlight was profitability resilience: EBIT reached 522.70 million US dollars, up 20.80% year over year and above prior estimates, reflecting favorable mix, operating expense discipline, and scale benefits. In the business mix, transcatheter heart valve therapy contributed 1.46 billion US dollars (83.68% of total), while surgical heart valve therapy contributed 284.10 million US dollars during a quarter in which total company sales grew 13.63% year over year.
Current Quarter Outlook
Transcatheter Heart Valve Therapy
The transcatheter heart valve franchise enters the quarter with supportive coverage tailwinds and solid procedural momentum. After the updated national coverage decision in the U.S., management reiterated its full-year outlook and emphasized that implementation will take time to filter through hospital scheduling and payer processes, which may stagger the growth curve across quarters rather than deliver an immediate step-change. With that backdrop, the current-quarter revenue estimate of 1.68 billion US dollars implies continued healthy device pull-through and stable pricing, while the 24.19% projected year-over-year increase in adjusted EPS reflects expected operating leverage on the mid-teens top-line growth base.
Mix is an important swing factor. The franchise benefits when procedural mix tilts toward higher-value valve sizes and more complex anatomies, but that also elevates clinical-support costs and case times. The balance between utilization growth and resource intensity will shape gross margin for the quarter relative to the 77.46% baseline from last quarter. Management’s 2026 guide for 8%–9% growth in TAVR suggests that, while growth is not explosive, it is consistent and well aligned with capacity expansion across major centers.
U.S. procedure volumes, hospital staffing, and reimbursement timing remain the primary operational variables. The company indicated the coverage-policy update requires time to translate into higher realized procedure counts; accordingly, the quarter’s performance is likely to hinge on how quickly centers incorporate the revised criteria into scheduling and how throughput evolves in cath labs. International performance, including EMEA and Asia-Pacific, can provide a cushion if U.S. throughput varies week to week, though currency and country-specific dynamics can influence reported results.
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Recent regulatory catalysts strengthen the TMTT setup for this quarter and beyond. U.S. approval of the PASCAL Precision system for tricuspid valve repair and approval of PASCAL Ace with Capture Clarity for degenerative mitral TEER expand the addressable treated population and provide additional physician-choice options within TEER. While this quarter likely represents an early commercialization phase for these indications, case starts, training cadence, and launch execution will begin to show up in order patterns and backlog conversion.
The TMTT platform’s medium-term growth algorithm ties to indication expansion, site activation velocity, and clinical evidence density. The quarter should reveal initial adoption signals for the new indications, including the pace at which high-volume U.S. centers integrate the tricuspid repair workflow into existing TEER programs. Given the inherently staged nature of complex structural heart launches—training, proctoring, and patient selection—contributions may be back-half weighted, but the approvals are meaningful building blocks for sustained growth.
Full-year context adds further support: management’s 2026 framework points to TMTT sales of 0.76–0.78 billion US dollars, which, coupled with expanding U.S. access and ongoing international rollouts, suggests a ramp trajectory that can positively influence mix and profit conversion over time. This quarter’s contribution should be sized as a foundation-setting step, with a more visible impact as 2026 progresses.
Quarterly Stock Drivers and What Could Move the Tape
Earnings-versus-consensus delta is the first-order driver. With current-quarter estimates calling for 1.68 billion US dollars of revenue and 0.74 in adjusted EPS, modest beats on either line—particularly if accompanied by a stable or improving gross margin backdrop—would likely be received favorably. Conversely, if hospital throughput or reimbursement implementation lags reduce near-term TAVR volume capture, investors may scrutinize the exit rate into the fourth quarter and any commentary about cadence into 2027.
Regulatory and clinical catalysts form a second cluster of drivers. Investor attention remains on clinical evidence expansion, including ongoing evaluations that could broaden the eligible patient pool for transcatheter interventions over time. Commentary around adoption trends following the U.S. approvals for tricuspid and degenerative mitral TEER will be parsed for early signs of acceleration in referral patterns, learning-curve effects on procedure times, and any updates on reimbursement pathways.
Legal and operating considerations round out the near-term sensitivities. Patent litigation affecting transcatheter mitral and tricuspid repair systems remains an overhang to monitor; while it does not typically alter quarter-to-quarter device demand, it can influence sentiment and perceived risk to long-term economics. On operations, foreign exchange, manufacturing cost absorption, and geographic mix can nudge gross margin either way, so any color on currency headwinds or production efficiencies will be important inputs for modeling the margin trajectory into year-end.
Analyst Opinions
Recent sell-side commentary skews decisively positive. Among the latest notes identified between late June and mid-October, the ratio of bullish to bearish stances is 8:0, with one neutral/market-perform observation mixed in; the majority view is unambiguously bullish. Price targets cited in the recent period span approximately 90 to 115 US dollars, signaling confidence in double-digit earnings growth and a supportive multi-quarter catalyst path.
The constructive side emphasizes three recurring themes. First, U.S. policy momentum: analysts highlight the updated national coverage criteria for transcatheter aortic valve procedures as a medium-term tailwind, even as they acknowledge that real-world implementation can be staged across hospitals and regions. Second, product catalysts: approvals for PASCAL Precision in tricuspid repair and PASCAL Ace with Capture Clarity in degenerative mitral TEER add breadth to the repair toolkit and are seen as incremental drivers that enhance procedure addressability and physician engagement. Third, execution against guidance: with the company reaffirming 2026 targets earlier in the fall, several analysts see scope for sustained revenue growth with operating leverage, particularly if mix modestly tilts toward higher-value interventions.
Representative views from well-followed firms align with this majority stance. Multiple analysts maintain Buy/Outperform ratings, with targets clustered near or above the low 100s in US dollars, citing the combination of stable TAVR fundamentals, favorable policy context, and expanding TMTT indications. One widely followed brokerage lifted its target above 100 US dollars, underscoring improved confidence in transcatheter repair adoption following recent FDA clearances. Another reiterated a Buy and pointed to national coverage changes as supportive of U.S. procedure growth in the coming quarters. Even where targets were adjusted near the 90 US dollars area, the tone remained constructive, framed around balanced risk-reward and recognition of upcoming clinical and commercial milestones.
The majority analysis also details what would validate the bullish case near term. Investors are looking for confirmation that revenue can compound in the low-double-digit range while adjusted EPS grows at a faster clip, consistent with the 24.19% year-over-year estimate this quarter. They also want to see that gross margin can hold near the high-70s percentage area through mix, cost control, and production scale, and that TAVR volumes in the U.S. reflect the progressive implementation of coverage updates. Early read-throughs on tricuspid and degenerative mitral TEER uptake, including site activations and case counts, would further support the view that TMTT is positioned to add momentum into 2027.
Given the preponderance of positive commentary, the consensus into November 4, 2026 Post-Mkt leans toward an expectation of solid execution, mid-teens earnings growth, and clear evidence that newly approved repair indications are beginning to contribute. The bar is not excessive, but visibility into adoption timing and procedure throughput remains critical; guidance tone for the fourth quarter and early 2027 will likely dictate whether the stock’s multiple can expand on the back of durable growth and an increasingly diversified transcatheter portfolio.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments